Results 201 to 207 of about 29,271 (207)

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

New England Journal of Medicine, 2014
Jennifer A Woyach, Hatice Gulcin Ozer, Marc Zapatka   +2 more
exaly  

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2013
Ian W Flinn, Jan A Burger, William G Wierda   +2 more
exaly  

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

New England Journal of Medicine, 2018
Constantine S Tam, Mary Ann Anderson, Christiane Pott   +2 more
exaly  

Ibrutinib Resistance in Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2014
Shuhua Cheng, Ailin Guo, Christina Leslie   +2 more
exaly  

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Lancet, The
Eva Giné, Jan A Walewski, Martin Hutchings   +2 more
exaly  

Ibrutinib—a new standard treatment for relapsed mantle cell lymphoma?

Lancet, The, 2016
Peter Martin
exaly  

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial

Lancet, The
Ingrid Cecilia Glimelius, Toby A Eyre, Sunil Iyengar   +2 more
exaly